Chris Riley currently serves as Executive Vice President of Biotechnology at Danaher Corporation and Chief Executive Officer of Cytiva.As the core biotechnology business of Danaher, Cytiva provides researchers and biopharmaceutical companies with technical support spanning every stage from drug discovery to commercialization.In 2023, Cytiva was involved in the production of more than 90% of the world’s approved monoclonal antibodies.